27 March 2014 - The DUSC met on 6 February 2014 and reviewed the utilisation of the following medicines on the PBS:

• Imatinib mesylate (Glivec) - chronic myeloid leukaemia
• Dasatinib hydrochloride (Sprycel) - chronic myeloid leukaemia
• Nilotinib hydrochloride monohydrate (Tasigna) - chronic myeloid leukaemia
• Deferasirox (Exjade) - iron overload
• Deferiprone (Ferriprox) - iron overload

Insofar as imatinib mesylate, deferasirox and deferiprone were recommended by the PBAC many years ago, a link to the DUSC February 2013 Outcome Statement for these medicines has not been added; links to the February 2013 Outcome statement have only been added to the recent PBAC recommendations for dasatinib hydrochloride (2011/2) and nilotinib hydrochloride monohydrate (2011/2).